Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children
Sas, David J., Magen, Daniella, Hayes, Wesley, Shasha-Lavsky, Hadas, Michael, Mini, Schulte, Indra, Sellier-Leclerc, Anne-Laure, Lu, Jiandong, Seddighzadeh, Ali, Habtemariam, Bahru, McGregor, Tracy L., Fujita, Kenji P., Frishberg, Yaacov, Bacchetta, Justine, Baudouin, Véronique, Becker-Cohen, Rachel, Tzvi Behr, Shimrit, Ben-Shalom, Efrat, Berdaguer, Maria, Bockenhauer, Detlef, Cochat, Pierre, Coenen, Martin, Cramer, Carl H., Deschênes, Georges, Dossier, Claire, Doye, Emilie, Feldman, Liat Feraru, Hohenadel, Maximilian, Kaguelidou, Florentia, Zebegret, Irina Libinson, Lieske, John C., Maisin, Anne, Milliner, Dawn S., Plonsky Toder, Moran, Pollack, Shirley, Portefaix, Aurélie, Ranchin, Bruno, Rinat, Choni, Safdar, Adnan, Schalk, Gesa, Srivaths, Poyyapakkam R., Tran, Cheryl L., Van't Hoff, William, Weinbrand-Goichberg, Jenny, Weissman, Irith
Published in Genetics in medicine (01.03.2022)
Published in Genetics in medicine (01.03.2022)
Get full text
Journal Article